Literature DB >> 22850755

Haematological cancer: Redefining myeloma.

S Vincent Rajkumar, Giampaolo Merlini, Jesus F San Miguel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22850755     DOI： 10.1038/nrclinonc.2012.128

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Diagnosis of smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Dirk Larson; Robert A Kyle
Journal:  N Engl J Med       Date:  2011-08-04       Impact factor: 91.245

2.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

Review 3.  Treatment of multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Nat Rev Clin Oncol       Date:  2011-04-26       Impact factor: 66.675

4.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

5.  Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.

Authors:  Ernesto Pérez-Persona; Gema Mateo; Ramón García-Sanz; María-Victoria Mateos; Natalia de Las Heras; Alfonso García de Coca; José M Hernández; Josefina Galende; Guillermo Martín-Nuñez; Abelardo Bárez; José M Alonso; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel; María-Belén Vidriales
Journal:  Br J Haematol       Date:  2009-10-11       Impact factor: 6.998

6.  Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden.

Authors:  M Hjorth; L Hellquist; E Holmberg; B Magnusson; S Rödjer; J Westin
Journal:  Eur J Haematol       Date:  1993-02       Impact factor: 2.997

Review 7.  Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.

Authors:  R A Kyle; S V Rajkumar
Journal:  Leukemia       Date:  2008-10-30       Impact factor: 11.528

8.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

Authors:  Robert A Kyle; Ellen D Remstein; Terry M Therneau; Angela Dispenzieri; Paul J Kurtin; Janice M Hodnefield; Dirk R Larson; Matthew F Plevak; Diane F Jelinek; Rafael Fonseca; Lee Joseph Melton; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

9.  Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; O Mora; C Tinelli; D Valentini; S Brugnatelli; R Spanedda; A De Paoli; L Barbarano; M Di Stasi; M Giordano; C Delfini; G Nicoletti; C Bergonzi; E Rinaldi; L Piccinini; E Ascari
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640
  9 in total
  15 in total

1.  Haematological cancer: Treatment of smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Robert A Kyle
Journal:  Nat Rev Clin Oncol       Date:  2013-09-03       Impact factor: 66.675

Review 2.  Smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Ola Landgren; María-Victoria Mateos
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

Review 3.  The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.

Authors:  Jo Caers; Carlos Fernández de Larrea; Xavier Leleu; Roy Heusschen; Niklas Zojer; Olivier Decaux; Efstathios Kastritis; Monique Minnema; Artur Jurczyszyn; Yves Beguin; Ralph Wäsch; Antonio Palumbo; Meletios Dimopoulos; Maria Victoria Mateos; Heinz Ludwig; Monika Engelhardt
Journal:  Oncologist       Date:  2016-02-26

4.  Natural history and outcome of light chain deposition disease.

Authors:  Rabya H Sayed; Ashutosh D Wechalekar; Janet A Gilbertson; Paul Bass; Shameem Mahmood; Sajitha Sachchithanantham; Marianna Fontana; Ketna Patel; Carol J Whelan; Helen J Lachmann; Philip N Hawkins; Julian D Gillmore
Journal:  Blood       Date:  2015-09-21       Impact factor: 22.113

5.  Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma.

Authors:  C Fernández de Larrea; R Jiménez; L Rosiñol; E Giné; N Tovar; M T Cibeira; F Fernández-Avilés; C Martínez; M Rovira; J Bladé
Journal:  Bone Marrow Transplant       Date:  2013-09-30       Impact factor: 5.483

Review 6.  Myeloma today: Disease definitions and treatment advances.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2016-01       Impact factor: 10.047

7.  Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.

Authors:  S V Rajkumar; V Gupta; R Fonseca; A Dispenzieri; W I Gonsalves; D Larson; R P Ketterling; J A Lust; R A Kyle; S K Kumar
Journal:  Leukemia       Date:  2013-03-21       Impact factor: 11.528

8.  Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.

Authors:  J T Larsen; S K Kumar; A Dispenzieri; R A Kyle; J A Katzmann; S V Rajkumar
Journal:  Leukemia       Date:  2012-10-16       Impact factor: 11.528

9.  High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma.

Authors:  Saurabh Chhabra; Sandeep Jain; Caroline Wallace; Feng Hong; Bei Liu
Journal:  J Hematol Oncol       Date:  2015-06-25       Impact factor: 17.388

10.  A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients.

Authors:  J Bae; R Prabhala; A Voskertchian; A Brown; C Maguire; P Richardson; G Dranoff; K C Anderson; N C Munshi
Journal:  Leukemia       Date:  2014-05-14       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.